News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PsiOxus Therapeutics Limited Launches Phase I/II Clinical Trial of Oncolytic Vaccine With Dosing of Patient With Metastatic Cancer


9/26/2012 8:38:59 AM

OXFORD, England--(BUSINESS WIRE)--PsiOxus Therapeutics, Ltd. (PsiOxus) has treated the first patient in its phase I/II clinical trial of ColoAd1 for the treatment of metastatic solid tumours. The Evolve (EValuating OncoLytic Vaccine Efficacy) study is the first clinical trial of the systemically available oncolytic vaccine ColoAd1, a highly potent, broad-spectrum, anti-cancer therapeutic capable of destroying tumour cells at minute concentrations.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES